ABSTRACT
In order to affirm the cardioactive components in Fuzi, we identified a group of aminoalcohol- diterpenoid alkaloids in Fuzi using ultra high-performance liquid chromatography coupled with electrospray ionization mass spectrometer (UPLC-ESI-MS) method. Among a total of forty-one isolated ingredients, thirteen major aminoalcohol-diterpenoid alkaloids were identified by comparing their retention times and MS spectra with those of the reference substances. Moreover, Fuzi samples from different places of origin and with different processing methods were examined and their components displayed a pattern of high similarity, though the relative abundance varies probably due to their different processing methods. Furthermore, the cardiac effect of each identified alkaloid was individually evaluated using the isolated bullfrog heart perfusion experiment. Among the thirteen aminoalcohol diterpenoid alkaloids tested, six of them significantly enhanced the amplitude rates. Taken together, we affirm that the cardioactive components in Fuzi are aminoalcohol-diterpenoid alkaloids, shedding light on future studies of the mechanisms and development of these cardioactive compounds.
Subject(s)
Animals , Aconitum , Chemistry , Alkaloids , Chemistry , Amino Alcohols , Chemistry , Cardiotonic Agents , Chemistry , Chromatography, High Pressure Liquid , Drugs, Chinese Herbal , Chemistry , Heart , In Vitro Techniques , Plant Extracts , Chemistry , Rana catesbeiana , Spectrometry, Mass, Electrospray IonizationABSTRACT
<p><b>BACKGROUND</b>Recently, due to the rapid development of proteomic techniques, great advance has been made in many scientific fields. We aimed to use magnetic beads (liquid chip) based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) technology to screen distinctive biomarkers for lung adenocarcinoma (adCA), and to establish the diagnostic protein profiles.</p><p><b>METHODS</b>Using weak cation exchange magnetic beads (MB-WCX) to isolate and purify low molecular weight proteins from sera of 35 lung adCA, 46 benign lung diseases (BLDs) and 44 healthy individuals. The resulting spectra gained by anchor chip-MALDI-TOF-MS were analyzed by ClinProTools and a pattern recognition genetic algorithm (GA).</p><p><b>RESULTS</b>In the working mass range of 800 - 10 000 Da, 99 distinctive peaks were resolved in lung adCA versus BLDs, while 101 peaks were resolved in lung adCA versus healthy persons. The profile gained by GA that could distinguish adCA from BLDs was comprised of 4053.88, 4209.57 and 3883.33 Da with sensitivity of 80%, specificity of 93%, while that could separate adCA from healthy control was comprised of 2951.83 Da and 4209.73 Da with sensitivity of 94%, specificity of 95%. The sensitivity provided by carcinoembryonic antigen (CEA) in this experiment was significantly lower than our discriminatory profiles (P < 0.005). We further identified a eukaryotic peptide chain release factor GTP-binding subunit (eRF3b) (4209 Da) and a complement C3f (1865 Da) that may serve as candidate biomarkers for lung adCA.</p><p><b>CONCLUSION</b>Magnetic beads based MALDI-TOF-MS technology can rapidly and effectively screen distinctive proteins/polypeptides from sera of lung adCA patients and controls, which has potential value for establishing a new diagnostic method for lung adCA.</p>
Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Adenocarcinoma , Blood , Diagnosis , Lung Neoplasms , Blood , Diagnosis , Magnetics , Microspheres , Sensitivity and Specificity , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , MethodsABSTRACT
<p><b>AIM</b>To design and synthesize new phenyloxyisobutyric acid analogues as antidiabetic compounds.</p><p><b>METHODS</b>Eight new target compounds were synthesized by combination of lipophilic moieties and acidic moiety with nucleophilic replacement or Mitsunobu condensation. The eight compounds were confirmed by 1H NMR, 13C NMR, IR and MS.</p><p><b>RESULTS</b>In vitro insulin-sensitizing activity (3T3-L1 adipocyte) demonstrated, that the cultured glucose concentration of up-clear solution detected with GOD-POD assay were 5.942, 6.339, 6.226 and 6.512 mmol x L(-1), respectively, when rosiglitazone, pioglitazone, compounds A and B were added to the insulin-resistant system.</p><p><b>CONCLUSION</b>In vitro insulin-sensitizing activity of target compound A is in between that of rosiglitazone and pioglitazone, and activity of target compound B is slightly less than that of pioglitazone.</p>
Subject(s)
Animals , Mice , 3T3-L1 Cells , Adipocytes , Butyrates , Chemistry , Pharmacology , Hypoglycemic Agents , Chemistry , Pharmacology , Insulin , Pharmacology , Molecular Structure , PPAR gamma , PharmacologyABSTRACT
<p><b>AIM</b>To study the tissue distribution and excretion of bromotetrandrine (W198) in rats.</p><p><b>METHODS</b>The concentrations of W198 in biological samples were determined by an HPLC method with UV detection.</p><p><b>RESULTS</b>After a single i.v. dose of 20 mg x kg(-1) W198 in rats, the parent drug concentrations in tissues were higher than those in blood at the same time. Parent drug was mainly distributed in lung, kidney, heart and liver, the peak levels were attained at 0.25 h and decreasing at 2 h after dosing in most tissues. After a single iv dose of 20 mg x kg(-1) W198 in rats, the excretion of the parent drug in urine, feces and bile amounted to 0. 150%, 2.1% and 0.063% of the dose, respectively.</p><p><b>CONCLUSION</b>W198 was mostly distributed in lung. The parent drug excretion was less than 3% via urine, feces and bile.</p>
Subject(s)
Animals , Female , Male , Rats , Antineoplastic Agents , Chemistry , Pharmacokinetics , Urine , Benzylisoquinolines , Chemistry , Pharmacokinetics , Urine , Bile , Metabolism , Feces , Chemistry , Kidney , Metabolism , Liver , Metabolism , Lung , Metabolism , Molecular Structure , Myocardium , Metabolism , Rats, Wistar , Tissue DistributionABSTRACT
<p><b>AIM</b>To study the pharmacokinetics of bromotetrandrine (W198) in rats and beagle dogs.</p><p><b>METHODS</b>The concentrations of W198 in serum were determined using HPLC method with UV detection.</p><p><b>RESULTS</b>The pharmacokinetic parameters of W198 after single iv doses of W198 10, 20 and 40 mg x kg(-1) in rats were as follows: T1/2beta were 6.60, 7.36 and 6.77 h, AUC0-24 h were 3.797, 7.371 and 15.192 mg x h x L(-1), Vd were 7.14, 4.33 and 4.13 L x kg(-1), CL were 2.83, 2.60 and 2.71 L x (kg x h)(-1), respectively. The T1/2beta and AUCo-24 h of W198 after single im dose of W198 20 mg x kg(-1) in rats were 11.61 h and 12.646 mg x h x L(-1). The im bioavailability of W198 in rats was 56.9%. The T1/2beta, AUC0-24 h, Vd and CL of W198 after single iv dose of W198 5 mg x kg(-1) in beagle dogs were 11.72 h, 12.646 mg x h x L(-1), 0.70 L x kg(-1) and 0.46 L x (kg x h)(-1), respectively. The plasma protein binding ratio of W198 with human serum protein was 78.0%.</p><p><b>CONCLUSION</b>The absorption of W198 in rats was of first order kinetics.</p>